Although the levels of IL-18 and IL-1β were expectedly reduced in the TME by Gsdmd knockout or DSF treatment (Supplemental Figure 2Y), neutralizing IL-18 and IL-1β did not change the difference in tumor growth between Gsdmd–/– or DSF-treated mice and WT untreated mice (Supplemental Figure 2Z), nor the difference in lymphocyte infiltration and function (Supplemental Figure 2, AA and AB). This evidence concerns the gene IL1B and neoplasm.